Bessemer Group Inc. Sells 238,450 Shares of Repligen Corporation $RGEN

Bessemer Group Inc. trimmed its stake in Repligen Corporation (NASDAQ:RGEN) by 95.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,079 shares of the biotechnology company’s stock after selling 238,450 shares during the quarter. Bessemer Group Inc.’s holdings in Repligen were worth $1,614,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Brown Capital Management LLC boosted its holdings in shares of Repligen by 16.3% in the 2nd quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock valued at $125,036,000 after buying an additional 141,241 shares during the last quarter. Stephens Investment Management Group LLC lifted its stake in Repligen by 14.4% in the third quarter. Stephens Investment Management Group LLC now owns 598,356 shares of the biotechnology company’s stock valued at $79,982,000 after acquiring an additional 75,509 shares during the last quarter. Geneva Capital Management LLC grew its position in shares of Repligen by 239.6% in the 2nd quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock valued at $60,639,000 after acquiring an additional 343,991 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Repligen by 6.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 458,820 shares of the biotechnology company’s stock worth $61,331,000 after purchasing an additional 28,716 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Repligen by 3,219.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock valued at $51,422,000 after purchasing an additional 400,970 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on RGEN. Weiss Ratings cut Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, January 30th. Jefferies Financial Group set a $160.00 price objective on Repligen and gave the company a “hold” rating in a research report on Tuesday, October 28th. Barclays boosted their target price on Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. UBS Group raised their price target on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 16th. Finally, Wells Fargo & Company upped their price objective on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average target price of $179.62.

Repligen Price Performance

NASDAQ:RGEN opened at $142.18 on Monday. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The firm’s 50-day simple moving average is $161.90 and its 200 day simple moving average is $145.25. The firm has a market cap of $8.00 billion, a price-to-earnings ratio of 7,112.56, a P/E/G ratio of 2.59 and a beta of 1.13.

Insider Activity

In other Repligen news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the transaction, the director directly owned 91,821 shares of the company’s stock, valued at $14,783,181. The trade was a 0.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO James Bylund sold 2,191 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 49,657 shares of company stock worth $7,721,077. Corporate insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.